Saltar al contenido
Merck

840465P

Avanti

18:0 PG

Avanti Research - A Croda Brand

Sinónimos:

1,2-dioctadecanoyl-sn-glycero-3-phospho-(1′racglycerol) (sodium salt); DSPG; PG(18:0/18:0); 110649

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

25 MG
MXP 2,150.00
200 MG
MXP 6,225.00
1 G
MXP 16,046.00

MXP 2,150.00


Check Cart for Availability

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
25 MG
MXP 2,150.00
200 MG
MXP 6,225.00
1 G
MXP 16,046.00

About This Item

Fórmula empírica (notación de Hill):
C42H82O10PNa
Número de CAS:
Peso molecular:
801.06
Número MDL:
Código UNSPSC:
51191904
NACRES:
NA.25

MXP 2,150.00


Check Cart for Availability

Solicitar un pedido a granel

descripción

1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt)

Ensayo

>99% (TLC)

Formulario

powder

envase

pkg of 1 × 1 g (840465P-1g)
pkg of 1 × 200 mg (840465P-200mg)
pkg of 1 × 25 mg (840465P-25mg)

fabricante / nombre comercial

Avanti Research - A Croda Brand

tipo de lípido

phospholipids
cardiolipins

temp. de almacenamiento

−20°C

cadena SMILES

[Na+].[P](=O)([O-])(OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC)OCC(O)CO

InChI

1S/C42H83O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h39-40,43-44H,3-38H2,1-2H3,(H,47,48);/q;+1/p-1/t39?,40-;/m1./s1

Clave InChI

YNQYZBDRJZVSJE-QTOMIGAPSA-M

Envase

20 mL Clear Glass Screw Cap Vial (840465P-1g)
5 mL Amber Glass Screw Cap Vial (840465P-200mg)
5 mL Amber Glass Screw Cap Vial (840465P-25mg)

Información legal

Avanti Research is a trademark of Avanti Polar Lipids, LLC

también adquirido normalmente con este producto

Referencia del producto
Descripción
Precios

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Lavanya Visvabharathy et al.
PLoS pathogens, 16(4), e1008443-e1008443 (2020-04-29)
Staphylococcus aureus (SA) is the causative agent of both skin/soft tissue infections as well as invasive bloodstream infections. Though vaccines have been developed to target both humoral and T cell-mediated immune responses against SA, they have largely failed due to
N Basaran Mutlu-Agardan et al.
Journal of liposome research, 1-12 (2020-04-16)
Amphotericin B (AmB) is a very potent antibiotic which still remains as the gold standard for the treatment of systemic fungal infections. AmB is a member of Biopharmaceutical Classification System Class IV, mainly characterized by its poor solubility and low
Brenda L Kessenich et al.
ACS omega, 5(21), 12154-12161 (2020-06-18)
Amphiphilic molecules can alter the wettability of soil minerals. To determine how the headgroup chemistry of amphiphiles determines these effects, we investigate a system of the clay montmorillonite with long-chain phospholipids. We use phosphatidylglycerol (PG) phospholipids to contrast with our
Noel Vera-González et al.
Journal of biomedical materials research. Part A, 108(11), 2263-2276 (2020-05-05)
Fungal infections can cause significant patient morbidity and mortality. Nanoparticle therapeutics have the potential to improve treatment of these infections. Here we report the development of liposomal nanoparticles incorporating anidulafungin, a potent antifungal, with the goal of increasing its solubility
Parvin Zamani et al.
Life sciences, 252, 117646-117646 (2020-04-10)
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells causing resistance to immunotherapies in cancer tumors. In the current study, various immunogenic and therapeutic features of the combination therapies with non-liposomal Doxorubicin (Dox) and the E75 immunogenic peptide (Pep), derived from the

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico